Does admission acetylsalicylic acid uptake in hospitalized COVID-19 patients have a protective role? Data from the Spanish SEMI-COVID-19 Registry.

Autor: Formiga F; Internal Medicine Department, Bellvitge University Hospital, Bellvitge Biomedical Research Institute-IDIBELL, University of Barcelona, L'Hospitalet de Llobregat, 08907, Barcelona, Spain. fformiga@bellvitgehospital.cat., Rubio-Rivas M; Internal Medicine Department, Bellvitge University Hospital, Bellvitge Biomedical Research Institute-IDIBELL, University of Barcelona, L'Hospitalet de Llobregat, 08907, Barcelona, Spain., Mora-Luján JM; Internal Medicine Department, Bellvitge University Hospital, Bellvitge Biomedical Research Institute-IDIBELL, University of Barcelona, L'Hospitalet de Llobregat, 08907, Barcelona, Spain., Escudero SC; Internal Medicine Department, 12 de Octubre University Hospital, Madrid, Spain., Martinez RFM; Internal Medicine Department, Cabueñes Hospital, Gijón, Asturias, Spain., Mendez-Bailón M; Internal Medicine Department, Clinico San Carlos Hospital, Universidad Complutense, Madrid, Spain., Campo PD; Internal Medicine Department, Universitario Puerta de Hierro Hospital, Majadahonda, Madrid, Spain., Pérez AR; Internal Medicine Department, H. U. S. Juan de Alicante, Alicante, Spain., García-Sánchez FJ; Internal Medicine Department, Infanta Cristina University Hospital, Parla, Madrid, Spain., Alcalá-Pedrajas JN; Internal Medicine Department, Pozoblanco Hospital, Córdoba, Spain., Hernández SA; Internal Medicine Department, San Pedro de Logroño Hospital, Logroño, Spain., Milian AH; Internal Medicine Department, Son Llàtzer Universitario Hospital, Palma de Mallorca, Spain., Díez AL; Internal Medicine Department, Universitary Ourense Hospital, Ourense, Spain., Sánchez RG; Internal Medicine Department, Universitari I Politècnic La Fe Hospital, Valencia, Spain., Boixeda R; Internal Medicine Department, Mataro Hospital, Barcelona, Mataro, Spain., Vicente J; Internal Medicine Department, Sagunto Hospital, Valencia, Spain., Cortes B; Internal Medicine Department,, Alto Guadalquivir Hospital, Jaén, Andújar, Spain., Pérez CM; Internal Medicine Department, Clínico Universitario de Ferrol, A Coruña, Spain., Espartero MEG; Internal Medicine Department, Infanta Margarita de Cabra Hospital, Cordoba, Spain., Castro JL; Internal Medicine Department, Monforte de Lemos, Hospital, Lugo, Spain., Suárez SR; Internal Medicine Department, Universitario Virgen del Rocío Hospital, Sevilla, Spain., Varona JF; Internal Medicine Department, Hospital Universitario HM Montepríncipe Hospital, Madrid, Spain., Gomez-Huelgas R; Internal Medicine Department, Regional University Hospital of Málaga, Biomedical Research Institute of Málaga (IBIMA), University of Málaga (UMA), Málaga, Spain., Ramos-Rincón JM; Internal Medicine Department, Miguel Hernandez University of Elche, Alicante, Spain.
Jazyk: angličtina
Zdroj: Internal and emergency medicine [Intern Emerg Med] 2022 Apr; Vol. 17 (3), pp. 761-775. Date of Electronic Publication: 2021 Nov 29.
DOI: 10.1007/s11739-021-02870-1
Abstrakt: Acetylsalicylic acid (ASA) is widely used in the treatment and prevention of cardiovascular disorders. Our objective is to evaluate its possible protective role, not only in mortality but also in other aspects such as inflammation, symptomatic thrombosis, and intensive care unit (ICU) admission in hospitalized COVID-19 patients. We realized an observational retrospective cohort study of 20,641 patients with COVID-19 pneumonia collected and followed-up from Mar 1st, 2020 to May 1st, 2021, from the nationwide Spanish SEMI-COVID-19 Registry. Propensity score matching (PSM) was performed to determine whether treatment with ASA affected outcomes in COVID-19 patients. On hospital admission, 3291 (15.9%) patients were receiving ASA. After PSM, 3291 patients exposed to ASA and 2885 not-exposed patients were analyzed. In-hospital mortality was higher in the ASA group (30.4 vs. 16.9%, p < 0.001) in the global sample. After PSM, no differences were found between groups (30.4 vs. 30.3%, p = 0.938). There were no differences in inflammation, symptomatic thrombosis, or ICU admission. In conclusion, ASA intake is not associated with in-hospital mortality or any other health outcome evaluated after applying PSM analysis in a real-world large sample of hospitalized COVID-19 patients.
(© 2021. Società Italiana di Medicina Interna (SIMI).)
Databáze: MEDLINE
Externí odkaz: